Authorisation List

Authorisation List

Authorisation List

List of substances included in Annex XIV of REACH ("Authorisation List").

Companies that want to continue using a substance included in the Authorisation List after the sunset date need to prepare an application for authorisation, submit it before the latest application date and have a positive authorisation decision by the European Commission. The latest application date and the sunset date are specified in the Authorisation List.

Please be reminded that this list is provided for information purposes only. Only the text of Annex XIV as published in the Official Journal of the EU is authentic and produces legal effects.

4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated

covering well-defined substances and UVCB substances, polymers and homologues EC No.: - CAS No.: -
Entry No.
42
Latest application date
04-Jul-2019
1 September 2021 for the use of the substance in the production of spare parts as articles or as complex products for the repair of articles or complex products, the production of which ceased or will have ceased before the sunset date indicated in the entry for that substance, where that substance was used in the production of those articles or complex products and these cannot function as intended without that spare part and the spare part cannot be produced without that substance, and for the use of the substance (on its own or in a mixture) for the repair of such articles or complex products where that substance on its own or in a mixture was used in the production of those articles or complex products and they cannot be repaired otherwise than by using that substance.

22/06/2022 for uses as follows:
- for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746 of the European Parliament and of the Council (Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176)), in view of their use for the diagnosis, treatment or prevention of the coronavirus disease (COVID-19),
- in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19.
Sunset Date
04-Jan-2021
1 March 2023 for the use of the substance in the production of spare parts as articles or as complex products for the repair of articles or complex products the production of which ceased or will have ceased before the sunset date indicated in the entry for that substance, where that substance was used in the production of those articles or complex products and these cannot function as intended without those spare parts and the spare part cannot be produced without that substance, and for the use of the substance (on its own or in a mixture) for the repair of such articles or complex products, where that substance on its own or in a mixture was used in the production of those articles or complex products and they cannot be repaired otherwise than by using that substance.

22/12/2023 for uses as follows:
- for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, in view of their use for the diagnosis, treatment or prevention of COVID-19,
- in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19.
Exempted (categories of) uses
Intrinsic property(ies) referred to in Article 57
Endocrine disrupting properties (Article 57(f) - environment)
Review Periods
Date of inclusion in Authorisation List
13-Jun-2017
Regulation amending Annex XIV
Remarks
First published
16-Jun-2017

Help Help
Group members
This group of substance has the following member substances:
Results list is empty
Name EC / List no. CAS no. Association
Polyethylene glycol p-(1,1,3,3-tetramethylbutyl)phenyl ether 618-344-0 9002-93-1 Official source
2-{2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethanol 621-341-7 2315-61-9 Official source
20-[4-(1,1,3,3-tetramethylbutyl)phenoxy]-3,6,9,12,15,18-hexaoxaicosan-1-ol 219-682-8 2497-59-8 Official source
Poly(oxy-1,2-ethanediyl), α-[(1,1,3,3-tetramethylbutyl)phenyl]-ω-hydroxy- 618-541-1 9036-19-5 Official source
2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethanol 621-345-9 2315-67-5 Official source

EU Privacy Disclaimer

This website uses cookies to ensure you get the best experience on our websites.